More 3D Medicines, Inc. news
3D Medicines, Inc.HKEX: 1244

Voluntary announcement envafolimab supplemental application for conditional-to-regular approval transition approved by NMPA

Nov 18, 2026 at 6:07 AM EST · Issued by 3D Medicines, Inc. via HKEXnews

Filed with HKEX · Stock code 1244 · Nov 18, 2026 at 6:07 AM EST · 2 pages · English

On 6ix: 6ix.com/news/voluntary-announcement-envafolimab-supplemental-application-for-conditional-to-regular-approval-transition-approved-by-nmpa

3D Medicines, Inc. on 6ix

Earlier from 3D Medicines

  • Voluntary announcement latest progress in collaboration programs: positive data achieved in the Global Pivotal Phase 3 REGAL trial for 3D189Nov 17
  • Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026Nov 3
  • Voluntary announcement latest progress in collaboration programs: achievement of pre-specified number of events in the global pivotal phase 3 REGAL trial for 3D189Oct 29
  • Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026Oct 6
  • Change of principal share registrar and transfer officeOct 2
All 3D Medicines news releases↗

Follow 3D Medicines into a list and get an email when it puts out news.

Follow 3D Medicines
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer